Findings
major depression, cognitive impairment
SECONDARY
In this secondary analysis of a randomized clinical trial in 1008 patients with major depression, 27% exhibited pretreatment global cognitive impairment and significantly decreased brain response to a cognitive task as well as worse response to standard pharmacotherapy, defining what may be categorized as a cognitive biotype. Changes in cognitive symptoms over the course of treatment mediated the association between pretreatment cognitive status and improvement in overall symptoms and psychosocial functioning.